Fate Therapeutics Stock Forecast, Price & News

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 155.5% and is now trading at $60.79.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fate Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Fate Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fate Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Fate Therapeutics.

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.39. The biopharmaceutical company had revenue of $7.56 million for the quarter, compared to analysts' expectations of $7.49 million. Fate Therapeutics had a negative net margin of 810.13% and a negative return on equity of 35.51%. The company's quarterly revenue was up 211.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.40) earnings per share.
View Fate Therapeutics' earnings history.

12 brokers have issued 12 month price targets for Fate Therapeutics' shares. Their forecasts range from $30.00 to $71.00. On average, they anticipate Fate Therapeutics' stock price to reach $50.81 in the next twelve months. This suggests that the stock has a possible downside of 16.4%.
View analysts' price targets for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Kodiak Sciences (KOD), Twist Bioscience (TWST) and Halozyme Therapeutics (HALO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), 1877 (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.56%), State Street Corp (3.34%), Victory Capital Management Inc. (2.80%), ARK Investment Management LLC (1.66%), Jennison Associates LLC (1.17%) and Polaris Venture Management Co. V L.L.C. (0.98%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc.
View institutional ownership trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., State Street Corp, Point72 Asset Management L.P., Victory Capital Management Inc., BNP Paribas Arbitrage SA, Federated Hermes Inc., Squarepoint Ops LLC, and Nikko Asset Management Americas Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, and J Scott Wolchko.
View insider buying and selling activity for Fate Therapeutics.

FATE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., ARK Investment Management LLC, Cubist Systematic Strategies LLC, Morgan Stanley, SG Americas Securities LLC, JPMorgan Chase & Co., Segall Bryant & Hamill LLC, and Assenagon Asset Management S.A..
View insider buying and selling activity for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $60.79.

Fate Therapeutics has a market capitalization of $5.30 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Fate Therapeutics employs 178 workers across the globe.

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]